Waldemar Link and THINK Surgical announced the successful first use of Waldemar Link’s LinkSymphoKnee utilizing THINK Surgical’s TMINI Miniature Robotic System.
LinkSymphoKnee’s platform provides multiple bearing surface philosophies and proprietary implant coatings. Surgeons can seamlessly integrate LinkSymphoKnee’s streamlined instrumentation and reduced tray footprint into their personalized workflow to easily adapt with the TMINI Robotic System.
THINK Surgical received FDA 510(k) clearance for use of LinkSymphoKnee implants with the TMINI Miniature Robotic System in November 2024.
As these important milestones have been achieved, Peter Willenborg, CEO of LINK Group states that “with LinkSymphoKnee and TMINI System, we are setting a new standard in knee surgery support, ensuring our customers have the most advanced tools available to deliver exceptional patient care.”
“With this latest milestone, THINK Surgical takes another step forward in delivering on its commitment to provide implant choices on the TMINI robotics system to enable surgeon’s to provide patient specific treatment” said Stuart Simpson, CEO of THINK Surgical. “The freedom to choose an implant independent from the robotics system gives surgeons the potential to optimize patient care and we are delighted to include the LinkSymphoKnee on the list of available options.”
Waldemar Link and THINK Surgical announced the successful first use of Waldemar Link's LinkSymphoKnee utilizing THINK Surgical's TMINI Miniature Robotic System.
LinkSymphoKnee's platform provides multiple bearing surface philosophies and proprietary implant coatings. Surgeons can seamlessly integrate LinkSymphoKnee's streamlined...
Waldemar Link and THINK Surgical announced the successful first use of Waldemar Link’s LinkSymphoKnee utilizing THINK Surgical’s TMINI Miniature Robotic System.
LinkSymphoKnee’s platform provides multiple bearing surface philosophies and proprietary implant coatings. Surgeons can seamlessly integrate LinkSymphoKnee’s streamlined instrumentation and reduced tray footprint into their personalized workflow to easily adapt with the TMINI Robotic System.
THINK Surgical received FDA 510(k) clearance for use of LinkSymphoKnee implants with the TMINI Miniature Robotic System in November 2024.
As these important milestones have been achieved, Peter Willenborg, CEO of LINK Group states that “with LinkSymphoKnee and TMINI System, we are setting a new standard in knee surgery support, ensuring our customers have the most advanced tools available to deliver exceptional patient care.”
“With this latest milestone, THINK Surgical takes another step forward in delivering on its commitment to provide implant choices on the TMINI robotics system to enable surgeon’s to provide patient specific treatment” said Stuart Simpson, CEO of THINK Surgical. “The freedom to choose an implant independent from the robotics system gives surgeons the potential to optimize patient care and we are delighted to include the LinkSymphoKnee on the list of available options.”
Copy to clipboard 
